{"id":300963,"date":"2026-07-09T18:31:13","date_gmt":"2026-07-09T18:31:13","guid":{"rendered":"https:\/\/www.europesays.com\/se\/300963\/"},"modified":"2026-07-09T18:31:13","modified_gmt":"2026-07-09T18:31:13","slug":"prekliniska-resultat-med-resomelagon-i-artros","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/300963\/","title":{"rendered":"PREKLINISKA RESULTAT MED RESOMELAGON I ARTROS"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Forskningsbolaget Synact Pharma meddelar att tidiga prekliniska resultat visar att l\u00e4kemedelskandidaten resomelagon minskar artrosrelaterad inflammation och ledskada, vilket leder till minskad sm\u00e4rta genom aktivering av signalv\u00e4gar som fr\u00e4mjar uppl\u00f6sning av inflammation.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Det framg\u00e5r av ett pressmeddelande.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Resultaten presenterades vid en vetenskaplig session tillsammans med Synacts samarbetspartner inom Resovir, Universidade Federal de Minas Gerais i Brasilien.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Magnus Bernet +46 8 5191 7953<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nyhetsbyr\u00e5n Direkt<\/p>\n","protected":false},"excerpt":{"rendered":"STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Forskningsbolaget Synact Pharma meddelar att tidiga prekliniska resultat visar att l\u00e4kemedelskandidaten resomelagon minskar artrosrelaterad inflammation&hellip;\n","protected":false},"author":2,"featured_media":300964,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,34,31,33,32,30,12427],"class_list":["post-300963","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-synact-pharma"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116891450506879522","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/300963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=300963"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/300963\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/300964"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=300963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=300963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=300963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}